Risk factor
Very high price volatility
Profitability factor
Somewhat favourable analyst view
About
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles;...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD
Target Price
The average target price of 086900.KQ is 185343 and suggests 56% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
Buy
Sell